Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Braz J Infect Dis. 2020 Jun 27;:
Authors: Hage R, Steinack C, Schuurmans MM
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than viral load. Therapies for COVID-19 are investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment in COVID-19, based on the experience seen in solid organ transplant recipients who suffered from COVID-19.
PMID: 32603679 [PubMed - as supplied by publisher]
Source: Braz J Infect Dis - Category: Infectious Diseases Authors: Hage R, Steinack C, Schuurmans MM Tags: Braz J Infect Dis Source Type: research
More News: Allergy & Immunology | Coronavirus | COVID-19 | Infectious Diseases | Respiratory Medicine | SARS | Transplants